E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale

<p>Enfortumab vedotin (EV) is an antibody-drug conjugate targeting nectin-4 with a monomethyl auristatin E payload, a potent microtubule inhibitor. It is a standard of care in metastatic or locally advanced urothelial carcinoma in combination with pembrolizumab in the first line, and as monoth...

Full description

Saved in:
Bibliographic Details
Main Author: Elias B. A. Chandran (21431286) (author)
Other Authors: Saad Atiq (21431289) (author), Nicholas Simon (3938363) (author), Daniel Girardi (21431292) (author), Lisa Ley (15029088) (author), Lisa Cordes (6051101) (author), Ruchi Patel (326827) (author), Tzu-Fang Wang (4287079) (author), Andre R. Kydd (21431295) (author), Bernadette Redd (15022875) (author), Salah Boudjadi (14954152) (author), Ian Stukes (11674929) (author), Rouf Banday (18201848) (author), Elizabeth Smith (337984) (author), Dilara Akbulut (15172042) (author), Scot Niglio (18314842) (author), Sandeep Gurram (21431298) (author), Seth Steinberg (5440424) (author), Andrea B. Apolo (11172900) (author)
Published: 2025
Subjects:
Medicine
Cell Biology
Genetics
Physiology
Pharmacology
Biotechnology
Immunology
Cancer
Infectious Diseases
Rare genitourinary tumors
antibody-drug conjugates
enfortumab vedotin
pembrolizumab
bladder adenocarcinoma
urachal adenocarcinoma
bladder squamous cell carcinoma
refractory testicular cancer
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items